Cytochalasin D
Based on 100 publication(s) in Google Scholar
Cytochalasin D (Zygosporin A) is a potent actin polymerization inhibitor, could be derived from fungus. Cytochalasin D has cell-permeable activity. Cytochalasin D inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells. Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of Yap.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.0%
- No. CAS: 22144-77-0
- Fòrmula: C30H37NO6
- Peso molecular:507.62
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cytochalasin D
More- Signal Transduct Target Ther. 2025 Apr 28;10(1):139. [Abstract]
- Cell. 2026 Mar 19;189(6):1748-1767.e26. [Abstract]
- Adv Mater. 2025 Mar;37(9):e2415030. [Abstract]
- Nat Methods. 2023 Dec;20(12):2021-2033. [Abstract]
- Nat Biomed Eng. 2026 Jun 3. [Abstract]
- Nat Aging. 2025 Jun;5(6):1097-1113. [Abstract]
- Bioact Mater. 2026 Jun 17:65:644-662. [Abstract]
- Bioact Mater. 2023 Dec 14:34:37-50. [Abstract]
- Bioact Mater. 2022 Aug 16:21:110-128. [Abstract]
- J Extracell Vesicles. 2026 Feb;15(2):e70238. [Abstract]
- J Extracell Vesicles. 2025 Aug;14(8):e70146. [Abstract]
- J Extracell Vesicles. 2024 Apr;13(4):e12426. [Abstract]
- Bone Res. 2025 Feb 14;13(1):23. [Abstract]
- Adv Funct Mater. 2025 Aug 3.
- Nat Microbiol. 2024 Jul;9(7):1764-1777. [Abstract]
- Autophagy. 2023 Apr;19(4):1144-1163. [Abstract]
- Nat Commun. 2026 Jun 9. [Abstract]
- Nat Commun. 2024 Feb 7;15(1):1150. [Abstract]
- Nat Commun. 2022 Sep 26;13(1):5657. [Abstract]
- Circ Res. 2023 Jan 6;132(1):87-105. [Abstract]
- ACS Nano. 2025 Dec 26. [Abstract]
- ACS Nano. 2024 Nov 26;18(47):32602-32616. [Abstract]
- J Adv Res. 2025 Feb 13:S2090-1232(25)00077-3. [Abstract]
- J Adv Res. 2024 Apr:58:117-128. [Abstract]
- J Adv Res. 2024 Apr:58:79-91. [Abstract]
- Adv Sci (Weinh). 2025 Dec 22:e09056. [Abstract]
- Adv Sci (Weinh). 2025 Sep 3:e02788. [Abstract]
- Adv Sci (Weinh). 2025 Feb;12(7):e2413451. [Abstract]
- Cell Death Differ. 2026 Jun 24. [Abstract]
- Cell Death Differ. 2024 Feb;31(2):239-253. [Abstract]
- Biomaterials. 2022 Feb:281:121373. [Abstract]
- Research (Wash D C). 2025 Jan 22:8:0590. [Abstract]
- J Control Release. 2024 Aug 21:374:293-311. [Abstract]
- Cell Mol Biol Lett. 2023 Oct 27;28(1):87. [Abstract]
- Cell Mol Biol Lett. 2023 Jan 24;28(1):7. [Abstract]
- Small. 2026 Mar;22(18):e13435. [Abstract]
- Cancer Lett. 2022 Apr 28:532:215582. [Abstract]
- Cell Commun Signal. 2023 Oct 30;21(1):308. [Abstract]
- Adv Healthc Mater. 2025 Sep;14(25):e2500507. [Abstract]
- Mater Today Bio. 2025 Apr 17:32:101778. [Abstract]
- Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. [Abstract]
- Food Chem. 2025 Dec 25;496(Pt 1):146646. [Abstract]
- Food Chem. 2025 Jan 15;463(Pt 1):141196. [Abstract]
- Food Chem X. 2025 Sep 16:31:103046. [Abstract]
- Small Methods. 2026 Feb;10(4):e01688. [Abstract]
- Int J Biol Macromol. 2025 Jun;311(Pt 2):143759. [Abstract]
- Int J Biol Macromol. 2025 May;310(Pt 3):143473. [Abstract]
- Int J Biol Macromol. 2024 Jan;256(Pt 1):128336. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696. [Abstract]
- EMBO Mol Med. 2025 Dec 1. [Abstract]
- Cancer Immunol Res. 2025 Aug 29. [Abstract]
- ACS Appl Mater Interfaces. 2026 Apr 22;18(15):21500-21513. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jul 2;17(26):37601-37616. [Abstract]
- ACS Appl Mater Interfaces. 2025 Mar 19;17(11):16533-16547. [Abstract]
- Stem Cell Res Ther. 2024 Nov 15;15(1):431. [Abstract]
- Stem Cell Res Ther. 2024 Sep 6;15(1):284. [Abstract]
- Stem Cell Res Ther. 2024 May 1;15(1):127. [Abstract]
- ACS Appl Mater Interfaces. 2023 Oct 18;15(41):48038-48049. [Abstract]
- Stem Cell Res Ther. 2021 Oct 7;12(1):523. [Abstract]
- Cell Rep. 2023 Jun 6;42(6):112617. [Abstract]
- Cell Rep. 2022 Apr 19;39(3):110698. [Abstract]
- Cell Prolif. 2025 Jul 16:e70097. [Abstract]
- J Ginseng Res. 2023 Nov;47(6):784-794. [Abstract]
- Br J Pharmacol. 2023 Jul;180(14):1878-1896. [Abstract]
- Anal Chem. 2023 May 23;95(20):8088-8096. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):1135-1144. [Abstract]
- Front Immunol. 2021 Jun 1:12:684430. [Abstract]
- Cell Rep Phys Sci. 2025 Oct 15;6(10).
- Lipids Health Dis. 2022 Oct 25;21(1):107. [Abstract]
- Acta Neuropathol Commun. 2026 Apr 10;14(1):115. [Abstract]
- Cell Mol Life Sci. 2025 Feb 27;82(1):96. [Abstract]
- Int Endod J. 2026 Jun 2. [Abstract]
- J Cell Biol. 2026 Aug 3;225(8):e202509213. [Abstract]
- Int J Pharm. 2026 Jul 10:700:127037. [Abstract]
- Commun Biol. 2025 Jul 30;8(1):1134. [Abstract]
- Commun Biol. 2022 Mar 24;5(1):262. [Abstract]
- ACS Appl Polym Mater. 2026 Feb 25.
- J Nutr Biochem. 2024 Apr:126:109587. [Abstract]
- Sci Rep. 2025 Sep 26;15(1):33026. [Abstract]
- Langmuir. 2020 Sep 29;36(38):11374-11382. [Abstract]
- Eur J Cell Biol. 2024 May 28;103(2):151427. [Abstract]
- J Virol. 2025 Aug 25:e0022125. [Abstract]
- J Infect Dis. 2023 Nov 13;228(Suppl 7):S522-S535. [Abstract]
- J Virol. 2022 Dec 14;96(23):e0145322. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 May;1870(4):159610. [Abstract]
- Virus Res. 2020 Jan 15:276:197806. [Abstract]
- Biol Reprod. 2023 Sep 12;109(3):319-329. [Abstract]
- Theoretical and Applied Mechanics Letters. 2025 Aug 22.
- Int J Pept Res Ther. 2025 May 22.
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Sep 30.
- bioRxiv. 2025 Oct 2:2025.09.30.679611. [Abstract]
- bioRxiv. 2025 February 21.
- bioRxiv. 2025 March 06.
- Research Square Preprint. 2024 Feb 13.
- Research Square Preprint. 2023 May 30.
- Research Square Preprint. 2023 Apr 19.
- bioRxiv. 2023 Feb 5.
- Bioengineered. 2022 Apr;13(4):8548-8557. [Abstract]
- Mater Sci Eng C Mater Biol Appl. 2021 Mar:122:111939. [Abstract]
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
RT-PCR
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas YAP
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MRC5 | IC50 |
2.36 μM
Compound: 2; CytD
|
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by WST-1 assay
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by WST-1 assay
|
[PMID: 38283219] |
Cytochalasin D (3 and 10 μM; 30 min) causes retraction and arborization of COS-7 cells and conversion of F-actin from long fibers to punctate structures[1].
Cytochalasin D (0.3, 1, 3 and 10 μM; 30 min) concentration-dependently decreases the rate of actin depolymerization in COS-7 cells[1].
Cytochalasin D (1 μM; NIH3T3 cells) disrupts stress fibers, and induces phosphorylation of Yap, while cells maintain the original area and lost nuclear Yap localization[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:COS-7 cells[1]
-
Concentration:3 and 10 μM
-
Incubation Time:30 min
-
Result:Caused retraction and arborization of COS-7 cells and conversion of F-actin from long fibers to punctate structures.
-
Cell Line:COS-7 cells expressing YFP-actin[1]
-
Concentration:0.3, 1, 3 and 10 μM
-
Incubation Time:30 min
-
Result:Concentration-dependently decreased the rate of actin depolymerization in COS-7 cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 22144-77-0
-
Appearance Solid
-
Peso molecular 507.62
-
Fòrmula C30H37NO6
-
Color White to off-white
-
SMILES
C=C1[C@@H](O)[C@@]2([H])[C@@]3([C@H](OC(C)=O)/C=C/[C@](O)(C)C([C@@H](C)C/C=C/2)=O)[C@@]([C@H](CC4=CC=CC=C4)NC3=O)([H])[C@@H]1C
-
Synonyms
Zygosporin A; NSC 209835
-
Structure Classification
-
Initial Source
molds
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (100)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan. [Abstract]2025 Apr 28;10(1):139. PMID: 40289109 -
Cell
2026 Mar 19;189(6):1748-1767.e26. PMID: 41643675 -
Adv Mater
Self-Sustained Biophotocatalytic Nano-Organelle Reactors with Programmable DNA Switches for Combating Tumor Metastasis. [Abstract]2025 Mar;37(9):e2415030. PMID: 39797479 -
Nat Methods
Reconstruction of dynamic mammary mini gland in vitro for normal physiology and oncogenesis. [Abstract]2023 Dec;20(12):2021-2033. PMID: 37919421 -
Nat Biomed Eng
Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours. [Abstract]2026 Jun 3. PMID: 42236980 -
Nat Aging
Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice. [Abstract]2025 Jun;5(6):1097-1113. PMID: 40394225 -
Bioact Mater
Growth plate cartilage-targeting nanoparticles for pharmacological treatment of hypochondroplasia. [Abstract]2026 Jun 17:65:644-662. PMID: 42338508 -
Bioact Mater
Lysosomal destabilization: A missing link between pathological calcification and osteoarthritis. [Abstract]2023 Dec 14:34:37-50. PMID: 38173842 -
Bioact Mater
A novel decellularized matrix of Wnt signaling-activated osteocytes accelerates the repair of critical-sized parietal bone defects with osteoclastogenesis, angiogenesis, and neurogenesis. [Abstract]2022 Aug 16:21:110-128. PMID: 36093329
Cytochalasin D purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 Aug 16:21:110-128. [Abstract]
Cytochalasin D (CytoD, 2 μM, 1 h) destroyed the cytoskeleton of BMSCs cultured in the daCO-DM modified scaffold.
Cytochalasin D purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 Aug 16:21:110-128. [Abstract]
Cytochalasin D (CytoD, 2 μM, 1 h) reduced the AP activity of BMSCs cultured in the daCO-DM modified scaffold (Top: DMSO group; Bottom: CytoD group).
Cytochalasin D purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 Aug 16:21:110-128. [Abstract]
Cytochalasin D (CytoD, 2 μM, 1 h) reduced the expression of osteoblast marker genes in BMSCs cultured in the daCO-DM modified scaffold.
-
J Extracell Vesicles
Extracellular Vesicles Coordinate Bacterial Cloaking in Lung Epithelial Cells to Alleviate Acute Inflammatory Injury. [Abstract]2026 Feb;15(2):e70238. PMID: 41656978 -
J Extracell Vesicles
Exomeres From Adventitial Fibroblasts of Spontaneously Hypertensive Rats Promote Vascular Remodelling via Transferring Osteopontin. [Abstract]2025 Aug;14(8):e70146. PMID: 40767027 -
J Extracell Vesicles
Proton pump inhibitors enhance macropinocytosis-mediated extracellular vesicle endocytosis by inducing membrane v-ATPase assembly. [Abstract]2024 Apr;13(4):e12426. PMID: 38532609 -
Bone Res
Matrix stiffness regulates nucleus pulposus cell glycolysis by MRTF-A-dependent mechanotransduction. [Abstract]2025 Feb 14;13(1):23. PMID: 39952914 -
Cytochalasin D purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2025 Aug 3.
Typical confocal images of RAW 264.7 cells incubated with 100 μg/mL FITC/M-BSA@PSiNPs for 6 h, in the absence or presence of 50 μmol/L Pitstop 2, 100 μmol/L Methyl-β-cyclodextrin (MβCD), 50 μmol/L amiloride, or 1 μmol/L CytoD (scale bar = 40 μm).
Cytochalasin D purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2025 Aug 3.
CytoD (1 μM; 6 h), Mβ CD (100 μM; 6 h) inhibited the gene expression of IL-1β, IL-6, CCL2, IFN-β, CXCL10, and TNF-α in RAW 264.7 cells treated with 100 μg /mL-M-BSA@PSiNPs.
-
Nat Microbiol
2024 Jul;9(7):1764-1777. PMID: 38849624 -
Autophagy
2023 Apr;19(4):1144-1163. PMID: 36170234 -
Nat Commun
2026 Jun 9. PMID: 42259798 -
Nat Commun
The role of extracellular vesicle fusion with target cells in triggering systemic inflammation. [Abstract]2024 Feb 7;15(1):1150. PMID: 38326335 -
Nat Commun
Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells. [Abstract]2022 Sep 26;13(1):5657. PMID: 36163326 -
Circ Res
Liquid-Liquid Phase Separation of DDR1 Counteracts the Hippo Pathway to Orchestrate Arterial Stiffening. [Abstract]2023 Jan 6;132(1):87-105. PMID: 36475898 -
ACS Nano
Redox-Responsive Peptide Coacervates for Enhanced mRNA Delivery and Intracellular Release. [Abstract]2025 Dec 26. PMID: 41451635 -
ACS Nano
Three-Dimensional Semiconductor Network as Regulators of Energy Metabolism Drives Angiogenesis in Bone Regeneration. [Abstract]2024 Nov 26;18(47):32602-32616. PMID: 39530623 -
J Adv Res
A dual absorption pathway of novel oyster-derived peptide-zinc complex enhances zinc bioavailability and restores mitochondrial function. [Abstract]2025 Feb 13:S2090-1232(25)00077-3. PMID: 39955018 -
J Adv Res
Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages. [Abstract]2024 Apr:58:117-128. PMID: 37290606 -
J Adv Res
Infusion of GMSCs relieves autoimmune arthritis by suppressing the externalization of neutrophil extracellular traps via PGE2-PKA-ERK axis. [Abstract]2024 Apr:58:79-91. PMID: 37169220 -
Adv Sci (Weinh)
Hyperviscous Diabetic Bone Marrow Niche Impairs BMSCs Osteogenesis via TRPV2-Mediated Cytoskeletal-Nuclear Mechanotransduction. [Abstract]2025 Dec 22:e09056. PMID: 41431162 -
Adv Sci (Weinh)
Physiological pH Transition-Driven Protein Corona Dynamics Regulate Cellular Uptake and Inflammatory Responses of Silica Nanoparticles. [Abstract]2025 Sep 3:e02788. PMID: 40902197 -
Adv Sci (Weinh)
Microglia Process α-Synuclein Fibrils and Enhance their Pathogenicity in a TREM2-Dependent Manner. [Abstract]2025 Feb;12(7):e2413451. PMID: 39665233 -
Cell Death Differ
2026 Jun 24. PMID: 42337094 -
Cell Death Differ
TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53. [Abstract]2024 Feb;31(2):239-253. PMID: 38182899 -
Biomaterials
Oral delivery of decanoic acid conjugated plant protein shell incorporating hybrid nanosystem leverage intestinal absorption of polyphenols. [Abstract]2022 Feb:281:121373. PMID: 35063742 -
Research (Wash D C)
Altered Atlas of Exercise-Responsive MicroRNAs Revealing miR-29a-3p Attacks Armored and Cold Tumors and Boosts Anti-B7-H3 Therapy. [Abstract]2025 Jan 22:8:0590. PMID: 39845707 -
J Control Release
Enhanced delivery of CRISPR/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy. [Abstract]2024 Aug 21:374:293-311. PMID: 39151831 -
Cell Mol Biol Lett
Cadmium promotes nonalcoholic fatty liver disease by inhibiting intercellular mitochondrial transfer. [Abstract]2023 Oct 27;28(1):87. PMID: 37884867 -
Cell Mol Biol Lett
LRP6/filamentous-actin signaling facilitates osteogenic commitment in mechanically induced periodontal ligament stem cells. [Abstract]2023 Jan 24;28(1):7. PMID: 36694134 -
Small
Dynamically Reprograms Mitochondrial Respiration to Augment Cuproptosis in Cancer Therapy. [Abstract]2026 Mar;22(18):e13435. PMID: 41653427 -
Cancer Lett
Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells. [Abstract]2022 Apr 28:532:215582. PMID: 35122876 -
Cell Commun Signal
Regulation of the integrin αVβ3- actin filaments axis in early osteogenic differentiation of human mesenchymal stem cells under cyclic tensile stress. [Abstract]2023 Oct 30;21(1):308. PMID: 37904190 -
Adv Healthc Mater
Lipoprotein-Based Nanocatalyst Enables Targeted Treatment of APAP-Induced Liver Injury via Enhanced Macropinocytosis. [Abstract]2025 Sep;14(25):e2500507. PMID: 40411876 -
Mater Today Bio
Membrane biomimetic nanoenzyme-incorporated hybrid glycyrrhizic acid hydrogel for precise mitochondrial ROS scavenging for osteoarthritis treatment. [Abstract]2025 Apr 17:32:101778. PMID: 40290887 -
Clin Cancer Res
CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma. [Abstract]2024 Sep 13;30(18):4179-4189. PMID: 39052240 -
Food Chem
Development and characterization of a walnut protein hydrolysate-Fe-vitamin C complex: Enhancing iron bioavailability through phytase-assisted modification. [Abstract]2025 Dec 25;496(Pt 1):146646. PMID: 41086629 -
Food Chem
Absorption and transport mechanism of colloidal nanoparticles (CNPs) in lamb soup based on Caco-2 cell. [Abstract]2025 Jan 15;463(Pt 1):141196. PMID: 39260179 -
Food Chem X
Preparation, characterization, assembly, and stability of walnut peptide - zinc complexes and its ability to promote zinc transport in Caco-2 cells. [Abstract]2025 Sep 16:31:103046. PMID: 41036460 -
Small Methods
Intracellular mRNA Delivery via Lambda DNA-Based Viscoelastic Mechanoporation in Hyperbolic Microfluidic Channel. [Abstract]2026 Feb;10(4):e01688. PMID: 41580930 -
Int J Biol Macromol
A dual-peptides and specific promoter-modified nano gene delivery system for myocardial hypertrophy treatment. [Abstract]2025 Jun;311(Pt 2):143759. PMID: 40319986 -
Int J Biol Macromol
UBTD2 protein molecules emerges as a key prognostic protein marker in glioma: Insights from integrated omics and machine learning analysis of GRM7, NCAPG, CEP55, and other biomarkers. [Abstract]2025 May;310(Pt 3):143473. PMID: 40286967 -
Int J Biol Macromol
Dissecting the early and late endosomal pathways of Singapore grouper iridovirus by single-particle tracking in living cells. [Abstract]2024 Jan;256(Pt 1):128336. PMID: 38013078 -
Cell Mol Gastroenterol Hepatol
2021;11(3):683-696. PMID: 33075564 -
EMBO Mol Med
Corneal biomechanical cues mediated by PAI-2: the origin of PM2.5-induced corneal disease. [Abstract]2025 Dec 1. PMID: 41326717 -
Cancer Immunol Res
Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma. [Abstract]2025 Aug 29. PMID: 40879086 -
ACS Appl Mater Interfaces
2026 Apr 22;18(15):21500-21513. PMID: 41968920 -
ACS Appl Mater Interfaces
Hydrogel Enhanced Organoid Multidirectional Differentiation via Yap/Tead4 Mechanotransduction for Accelerated Tissue Regeneration. [Abstract]2025 Jul 2;17(26):37601-37616. PMID: 40550785 -
ACS Appl Mater Interfaces
Intranasal Delivery of Hydrophobic AC5216 Loaded Nanoemulsion into Brain To Alleviate Chronic Unpredictable Stress-Induced Depressive-like Behaviors. [Abstract]2025 Mar 19;17(11):16533-16547. PMID: 40063900 -
Stem Cell Res Ther
AGEs impair osteogenesis in orthodontic force-induced periodontal ligament stem cells through the KDM6B/Wnt self-reinforcing loop. [Abstract]2024 Nov 15;15(1):431. PMID: 39548506 -
Stem Cell Res Ther
The cytoskeleton dynamics-dependent LINC complex in periodontal ligament stem cells transmits mechanical stress to the nuclear envelope and promotes YAP nuclear translocation. [Abstract]2024 Sep 6;15(1):284. PMID: 39243052 -
Stem Cell Res Ther
MSCs promote the efferocytosis of large peritoneal macrophages to eliminate ferroptotic monocytes/macrophages in the injured endometria. [Abstract]2024 May 1;15(1):127. PMID: 38693589 -
ACS Appl Mater Interfaces
Chiral Cell Nanomechanics Originated in Clockwise/Counterclockwise Biofunctional Microarrays to Govern the Nuclear Mechanotransduction of Mesenchymal Stem Cells. [Abstract]2023 Oct 18;15(41):48038-48049. PMID: 37812566 -
Stem Cell Res Ther
Regulation of the integrin αVβ3- actin filaments axis in early osteogenesis of human fibroblasts under cyclic tensile stress. [Abstract]2021 Oct 7;12(1):523. PMID: 34620239 -
Cell Rep
Resolvin D1 reprograms energy metabolism to promote microglia to phagocytize neutrophils after ischemic stroke. [Abstract]2023 Jun 6;42(6):112617. PMID: 37285269 -
Cell Rep
Bladder epithelial cell phosphate transporter inhibition protects mice against uropathogenic Escherichia coli infection. [Abstract]2022 Apr 19;39(3):110698. PMID: 35443182 -
Cell Prolif
2025 Jul 16:e70097. PMID: 40670295 -
J Ginseng Res
Ginsenoside Rg5 promotes wound healing in diabetes by reducing the negative regulation of SLC7A11 on the efferocytosis of dendritic cells. [Abstract]2023 Nov;47(6):784-794. PMID: 38107390 -
Br J Pharmacol
2023 Jul;180(14):1878-1896. PMID: 36727262 -
Anal Chem
Metabolic Footprinting-Based DNA-AuNP Encoders for Extracellular Metabolic Response Profiling. [Abstract]2023 May 23;95(20):8088-8096. PMID: 37155931 -
Emerg Microbes Infect
SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in an Arf6-dependent manner. [Abstract]2022 Dec;11(1):1135-1144. PMID: 35343395 -
Front Immunol
2021 Jun 1:12:684430. PMID: 34140954 -
-
Lipids Health Dis
Intervention time decides the status of autophagy, NLRP3 activity and apoptosis in macrophages induced by ox-LDL. [Abstract]2022 Oct 25;21(1):107. PMID: 36284323 -
Acta Neuropathol Commun
LCN2/SLC22A17 mediates the phagocytosis of GABAergic synapses by oligodendrocyte progenitor cells and contributes to cancer-induced pain and comorbid anxiety-like behaviors in mice. [Abstract]2026 Apr 10;14(1):115. PMID: 41964063 -
Cell Mol Life Sci
Glycocalyx hyaluronan removal-induced increasing of cell stiffness delays breast cancer cells progression. [Abstract]2025 Feb 27;82(1):96. PMID: 40011237 -
Int Endod J
2026 Jun 2. PMID: 42227345 -
J Cell Biol
Phosphatidylserine and RhoB connect PI4P and PA metabolism to maintain plasma membrane identity. [Abstract]2026 Aug 3;225(8):e202509213. PMID: 42360433 -
Int J Pharm
Novel Gemini surfactant-polyglutamic acid composite system enhances DNA delivery via a "Dual-Engine" uptake strategy. [Abstract]2026 Jul 10:700:127037. PMID: 42217812 -
Commun Biol
Inhibition of inner ear macrophage phagocytosis alleviates cisplatin-induced ototoxicity. [Abstract]2025 Jul 30;8(1):1134. PMID: 40739377 -
Commun Biol
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction. [Abstract]2022 Mar 24;5(1):262. PMID: 35332252 -
-
J Nutr Biochem
Calorie restriction mimetic, resveratrol, attenuates hepatic ischemia and reperfusion injury through enhancing efferocytosis of macrophages via AMPK/STAT3/S1PR1 pathway. [Abstract]2024 Apr:126:109587. PMID: 38262562 -
Sci Rep
Importin-7 promotes tension-induced osteogenesis by regulating RUNX2 nuclear translocation during orthodontic tooth movement. [Abstract]2025 Sep 26;15(1):33026. PMID: 41006735 -
Langmuir
2020 Sep 29;36(38):11374-11382. PMID: 32902993 -
Eur J Cell Biol
The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. [Abstract]2024 May 28;103(2):151427. PMID: 38820882 -
J Virol
SFTSV utilizes AXL/GAS6 for entry via PI3K-PLC-dependent macropinocytosis activated by AXL-kinase. [Abstract]2025 Aug 25:e0022125. PMID: 40853130 -
J Infect Dis
2023 Nov 13;228(Suppl 7):S522-S535. PMID: 37723997 -
J Virol
PIK-24 Inhibits RSV-Induced Syncytium Formation via Direct Interaction with the p85α Subunit of PI3K. [Abstract]2022 Dec 14;96(23):e0145322. PMID: 36416586 -
Biochim Biophys Acta Mol Cell Biol Lipids
Cytoskeleton regulates lipid droplet fusion and lipid storage by controlling lipid droplet movement. [Abstract]2025 May;1870(4):159610. PMID: 40189192 -
Virus Res
Muscovy duck reovirus enters susceptible cells via a caveolae-mediated endocytosis-like pathway. [Abstract]2020 Jan 15:276:197806. PMID: 31704247 -
Biol Reprod
Sperm induce macrophages extracellular trap formation via phagocytosis -dependent mechanism. [Abstract]2023 Sep 12;109(3):319-329. PMID: 37402702 -
-
-
-
-
bioRxiv
Phosphatidylserine and RhoB connect phosphatidylinositol 4-phosphate and phosphatidic acid metabolism at the plasma membrane. [Abstract]2025 Oct 2:2025.09.30.679611. PMID: 41256676 -
-
-
-
-
-
-
Bioengineered
The abnormal phosphorylation of the Rac1, Lim-kinase 1, and Cofilin proteins in the pathogenesis of Hirschsprung's disease. [Abstract]2022 Apr;13(4):8548-8557. PMID: 35322726 -
Mater Sci Eng C Mater Biol Appl
RNA-seq reveals correlations between cytoskeleton-related genes and the osteogenic activity of mesenchymal stem cells on strontium loaded titania nanotube arrays. [Abstract]2021 Mar:122:111939. PMID: 33641927
Solvente y solubilidad
DMSO : 25 mg/mL (49.25 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.46 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.46 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Shoji K, et, al. Cytochalasin D acts as an inhibitor of the actin-cofilin interaction. Biochem Biophys Res Commun. 2012 Jul 20;424(1):52-7. [Content Brief]
[2]. Flanagan MD, et, al. Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem. 1980 Feb 10;255(3):835-8. [Content Brief]
[3]. Catalano M, et, al. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2019 Dec 19;9(1):1703244. [Content Brief]
[4]. Wada K, et, al. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011 Sep;138(18):3907-14. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9700 mL | 9.8499 mL | 19.6998 mL | 49.2494 mL |
| 5 mM | 0.3940 mL | 1.9700 mL | 3.9400 mL | 9.8499 mL | |
| 10 mM | 0.1970 mL | 0.9850 mL | 1.9700 mL | 4.9249 mL | |
| 15 mM | 0.1313 mL | 0.6567 mL | 1.3133 mL | 3.2833 mL | |
| 20 mM | 0.0985 mL | 0.4925 mL | 0.9850 mL | 2.4625 mL | |
| 25 mM | 0.0788 mL | 0.3940 mL | 0.7880 mL | 1.9700 mL | |
| 30 mM | 0.0657 mL | 0.3283 mL | 0.6567 mL | 1.6416 mL | |
| 40 mM | 0.0492 mL | 0.2462 mL | 0.4925 mL | 1.2312 mL |
Cytochalasin D Related Classifications
HY-N6682 Related Classifications
Powered by Bioz